Certificate Course in Management of MASLD in Diabetes Care (CCMMDC)

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is fast becoming one of the most serious health concerns in diabetes care. Nearly two out of three people with type 2 diabetes are estimated to have MASLD, yet it often goes undiagnosed until advanced stages, when treatment options are limited. Beyond liver complications such as fibrosis, cirrhosis and hepatocellular carcinoma, MASLD also heightens the risk of cardiovascular disease (CVD) and metabolic deterioration, making it a double threat for people with diabetes.

This online certificate course has been carefully designed to bridge the knowledge and practice gap in managing MASLD alongside diabetes. Through structured, evidence-based modules, participants will gain the ability to recognize the pathophysiology and clinical spectrum of MASLD, apply non-invasive diagnostic tools and screening strategies in daily practice, implement comprehensive management approaches including lifestyle modification and appropriate pharmacological therapy, and address the unique aspects of MASLD in diabetes with an emphasis on patient empowerment and multidisciplinary collaboration. By the end of the course, the participants will be well equipped to detect MASLD early, manage it effectively and integrate liver health into diabetes care, thereby improving patient outcomes and enhancing their own professional competence.

Global Context and Need

MASLD, once considered a silent condition, is now recognized as a global epidemic that closely mirrors the rise in obesity, insulin resistance and type 2 diabetes. Current estimates suggest that up to 70% of individuals with type 2 diabetes have MASLD, with a significant proportion at risk of progressive liver fibrosis. The disease contributes not only to liver-related mortality but also stands as a strong independent risk factor for CVD, the leading cause of death in people with diabetes. Despite its scale, awareness, routine screening and structured management of MASLD remain limited across healthcare systems.

Recent international consensus reports, including those from the American Diabetes Association and leading hepatology societies, now recommend routine MASLD screening in all patients with diabetes. They emphasize the importance of early risk stratification using non-invasive tools and call for a stronger integration of MASLD management into diabetes care. In this backdrop, the urgent need for trained professionals to address the rising burden of MASLD makes this specialized program particularly timely and essential.

Course Impact

Through this course, participants will gain advanced knowledge of the underlying mechanisms of MASLD, its diagnostic approaches and its clinical spectrum. They will develop practical skills to apply non-invasive tools such as fibrosis scoring systems, Elastography and biochemical markers for the early identification of at-risk patients. They will also learn evidence-based strategies for management, ranging from dietary and lifestyle interventions to pharmacological therapies such as Resmetirom, GLP-1 receptor agonists, SGLT-2 inhibitors and pioglitazone, as well as surgical interventions in selected cases.

The course also explores the unique challenges MASLD poses in people with diabetes, particularly its impact on cardiovascular and renal health. Participants will be guided on how to educate and empower patients for sustainable lifestyle changes and long-term disease control, while strengthening their ability to work within a multidisciplinary team. By completing this certification, the participants will improve their capacity to deliver high-quality, comprehensive care in one of the most rapidly evolving and clinically relevant areas of diabetes management.